Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Cellular Therapy (GPC2-CAR T-Cells) for the Treatment of Children and Young Adults with Relapsed or Refractory Medulloblastoma and other Central Nervous System Embryonal Tumors

Trial Status: active

This phase I trial studies the side effects and best dose of GPC2-chimeric antigen receptor (CAR) T-cells in treating patients with children and young adults with medulloblastoma or other central nervous system (CNS) embryonal tumors (e.g., embryonal tumors with multilayered rosettes, atypical teratoid/rhabdoid tumors, pineoblastoma, CNS neuroblastoma, etc.) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Cellular therapy uses the body's own immune cells to target markers on the surface of tumor cells. This study uses a GPC2-CAR gene and a type of virus (retrovirus) in making the cellular therapy (GPC2-CAR T-cells). The CAR is genetically-engineered so that immune cells can recognize and respond to a specific molecule, which in this study is the GPC2 cell surface protein. The CAR molecule is combined with a patient's T-cells, which then helps the T-cells target the tumor cells in the body.